Dexamethasone: Effects on neointimal hyperplasia and vessel integrity

Cardiovascular Research

Volumn 68, Issue 3, 2005, Pages 350-352

  Fischer, J W ^a  

^a HEINRICH HEINE UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CELL ADHESION MOLECULE; CYCLOOXYGENASE 2; CYTOKINE; DEXAMETHASONE; DISEASE MODIFYING ANTIRHEUMATIC DRUG; I KAPPA B; I KAPPA B ALPHA; LIPOCORTIN 1; PACLITAXEL; PHOSPHOLIPASE A2; RAPAMYCIN;

ANTIINFLAMMATORY ACTIVITY; ARTERY INTIMA PROLIFERATION; CLINICAL TRIAL; CUSHING SYNDROME; DISEASE MODEL; DRUG ACTIVITY; DRUG EFFECT; DRUG ELUTING STENT; EDITORIAL; ENZYME INHIBITION; GENE EXPRESSION REGULATION; GLUCOSE METABOLISM; HEART INFARCTION; HEART MUSCLE REVASCULARIZATION; HUMAN; HYPERPLASIA; HYPERTENSION; IMMUNE DEFICIENCY; IMMUNOSUPPRESSIVE TREATMENT; LIPID METABOLISM; METABOLIC DISORDER; NONHUMAN; OSTEOPOROSIS; PERCUTANEOUS TRANSLUMINAL ANGIOPLASTY; PRIORITY JOURNAL; RESTENOSIS; SIDE EFFECT; SIGNAL TRANSDUCTION; THROMBOSIS;

ANIMALS; ANTI-INFLAMMATORY AGENTS; ARTERIES; ATHEROSCLEROSIS; CONSTRICTION, PATHOLOGIC; DEXAMETHASONE; HUMANS; HYPERPLASIA; MICE; MODELS, ANIMAL; TUNICA INTIMA;

EID: 27644500433     PISSN: 00086363     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cardiores.2005.09.008     Document Type: Editorial

References (16)

1. A.W. Clowes, M.A. Reidy, and M.M. Clowes Mechanisms of stenosis after arterial injury Lab Invest 49 1983 208 215
2. G.S. Mintz, J.J. Popma, A.D. Pichard, K.M. Kent, L.F. Satler, and C. Wong Arterial remodeling after coronary angioplasty: a serial intravascular ultrasound study Circulation 94 1996 35 43
3. M. O'Sullivan, S.D. Scott, N. McCarthy, N. Figg, L.M. Shapiro, and P. Kirkpatrick Differential cyclin E expression in human in-stent stenosis smooth muscle cells identifies targets for selective anti-restenosis therapy Cardiovasc Res 60 2003 673 683
4. R. Hoffmann, G.S. Mintz, G.R. Dussaillant, J.J. Popma, A.D. Pichard, and L.F. Satler Patterns and mechanisms of in-stent restenosis. A serial intravascular ultrasound study Circulation 94 1996 1247 1254
5. R. Kornowski, M.K. Hong, F.O. Tio, O. Bramwell, H. Wu, and M.B. Leon In-stent restenosis: contributions of inflammatory responses and arterial injury to neointimal hyperplasia J Am Coll Cardiol 31 1998 224 230
6. A. Segev, N. Nili, and B.H. Strauss The role of perlecan in arterial injury and angiogenesis Cardiovasc Res 63 2004 603 610
7. A. Farb, F.D. Kolodgie, J.Y. Hwang, A.P. Burke, K. Tefera, and D.K. Weber Extracellular matrix changes in stented human coronary arteries Circulation 110 2004 940 947
8. D. Rosner, N. McCarthy, and M. Bennett Rapamycin inhibits human in stent restenosis vascular smooth muscle cells independently of pRB phosphorylation and p53 Cardiovasc Res 66 2005 601 610
9. D.I. Axel, W. Kunert, C. Goggelmann, M. Oberhoff, C. Herdeg, and A. Kuttner Paclitaxel inhibits arterial smooth muscle cell proliferation and migration in vitro and in vivo using local drug delivery Circulation 96 1997 636 645
10. F. Saia, A. Marzocchi, and P.W. Serruys Drug-eluting stents. The third revolution in percutaneous coronary intervention Ital Heart J 6 2005 289 303
11. N.M.M. Pires, A. Schepers, B.L. van der Hoeven, M.R. de Vries, L.S.M. Boesten, and J.W. Jukema Histopathologic alterations following local delivery of dexamethasone to inhibit restenosis in murine arteries Cardiovasc Res 68 2005 415 424
12. X. Liu, Y. Huang, C. Hanet, M. Vandormael, V. Legrand, and J. Dens Study of antirestenosis with the BiodivYsio dexamethasone-eluting stent (STRIDE): a first-in-human multicenter pilot trial Catheter Cardiovasc Interv 60 2003 172 178
13. R. Hoffmann, R. Langenberg, P. Radke, A. Franke, R. Blindt, and J. Ortlepp Evaluation of a high-dose dexamethasone-eluting stent Am J Cardiol 94 2004 193 195
14. M. Moroi, L. Zhang, T. Yasuda, R. Virmani, H.K. Gold, and M.C. Fishman Interaction of genetic deficiency of endothelial nitric oxide, gender, and pregnancy in vascular response to injury in mice J Clin Invest 101 1998 1225 1232
15. N.M. Pires, B.L. vander Hoeven, M.R. de Vries, L.M. Havekes, B.J. van Vlijmen, and W.E. Hennink Local perivascular delivery of anti-restenotic agents from a drug-eluting poly(epsilon-caprolactone) stent cuff Biomaterials 26 2005 5386 5394
16. R.S. Schwartz, E.R. Edelman, A. Carter, N. Chronos, C. Rogers, and K.A. Robinson Drug-eluting stents in preclinical studies: recommended evaluation from a consensus group Circulation 106 2002 1867 1873